Denis Patrick
Private Equity Investor chez PFIZER, INC.
Profil
Denis Patrick, PHD is Vice President, WRDM and Head of Partnering Innovation, and Managing Partner of Pfizer Ventures.
Denis capitalizes upon his experience in evaluating external opportunities to identify and manage equity investments.
He currently has responsibility for Pfizer’s investments in AnTolRx, Aquinnah Pharmaceuticals, EvolveImmune Therapeutics, FoRx Therapeutics, Metabomed, MISSION Therapeutics and Palleon Pharma.
His prior investment responsibilities include Bolt Biotherapeutics (BOLT), eFFECTOR Therapeutics (EFTR), and NextCure (NXTC).
Previously, Denis served as Head of Oncology Licensing for Worldwide R&D at Pfizer from 2010 to 2018.
In this capacity some of his recent executed agreements included acquisitions of Medivation and BIND Therapeutics, and research licenses with CytomX, Stemcentrx, iTeos, BioAtla, Western Oncolytics, eFFECTOR, Cancer Research Therapeutics and Arvinas.
Prior to coming to Pfizer, Denis worked for several large pharma oncology organizations, including Merck, DuPont Pharma, and GSK.
He contributed significantly to several oncology drug discovery efforts that led to the approval of three marketed therapeutic agents including nelarabine, trametinib, and dabrafenib.
Denis received his BS in Biochemistry from SUNY, a MS in Biology from UCSD and a PhD in Biochemistry from the University of Pennsylvania.
Postes actifs de Denis Patrick
| Sociétés | Poste | Début |
|---|---|---|
| PFIZER, INC. | Private Equity Investor | 01/08/2010 |
eFFECTOR Therapeutics Operations, Inc.
 eFFECTOR Therapeutics Operations, Inc. Miscellaneous Commercial ServicesCommercial Services eFFECTOR Therapeutics Operations, Inc. discovers and develops translation regulators. It offers small molecule therapeutics that control gene expression for the treatment of cancer and other serious diseases. Its pipeline of translation regulators includes eFT508, eIF4E, and eIF4A. The company was founded by James R. Appleman, Kevin L. Eastwood, Siegfried Reich, Davide Ruggero, Kevan Shokat, and Stephen T. Worland in 2012 and is headquartered in San Diego, CA. | Director/Board Member | - |
MISSION Therapeutics Ltd.
 MISSION Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology MISSION Therapeutics Ltd. develops small molecule drugs targeting enzymes involved in cancer and other diseases. It focuses on selectively targeting deubiquitylating enzymes to treat cancer, neurodegenerative and other diseases. The company was founded by Stephen Jackson Philip, Xavier Jacq, Niall M. B. Martin and Keith Menear in 2011 and is headquartered in Cambridge, the United Kingdom. | Director/Board Member | - |
FoRx Therapeutics AG
 FoRx Therapeutics AG Pharmaceuticals: MajorHealth Technology FoRx Therapeutics AG operates as a biotechnology company developing a new generation of cancer drugs focusing on novel deoxyribonucleic acid (DNA) Replication Stress pathways activated in cancer. The firm also provides research and development services. The company was founded by Thanos Halazonetis and Sotirios K. Sotiriou in 2019 and is headquartered in Basel, Switzerland. | Director/Board Member | - |
Evolveimmune Therapeutics, Inc.
 Evolveimmune Therapeutics, Inc. BiotechnologyHealth Technology EvolveImmune Therapeutics Inc. engages in the provision of healthcare services. It offers immunotherapy platform to develop molecules for the treatment of oncology and immune diseases. The company was founded in 2019 and is headquartered in Westport, CT. | Director/Board Member | - |
Pfizer Venture Investments LLC
 Pfizer Venture Investments LLC Investment ManagersFinance Pfizer Ventures Investments LLC (Pfizer Ventures Investments) is a venture capital subsidiary of Pfizer Inc. founded in 2001. The firm is headquartered in New York. | Private Equity Investor | 01/04/2018 |
Palleon Pharmaceuticals, Inc.
 Palleon Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Palleon Pharmaceuticals, Inc. operates as biotechnology company. The firm discovers and develops immuno-oncology drugs, medicines, and therapies for the treatment of cancer diseases. It specializes in clinical development, and glyco-immune checkpoint inhibitors. The company was founded by Jim Broderick, Carolyn Bertozzi and Paul Crocker in 2015 and is headquartered in Waltham, MA. | Director/Board Member | 16/12/2021 |
Metabomed Ltd.
 Metabomed Ltd. Pharmaceuticals: MajorHealth Technology Metabomed Ltd. operates as a drug discovery company. It focuses in the field of cancer metabolism with a proprietary target identification platform based on computational biology and metabolomics. The company was founded by Eytan Ruppin, Tomer Shlomi and Eyal Gottlieb in 2013 and is headquartered in Yavne, Israel. | Director/Board Member | - |
Kestrel Therapeutics, Inc.
 Kestrel Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Kestrel Therapeutics, Inc. is a company that has two habitat restoration projects aimed at helping native animals that are at risk, specifically the American Kestrel and the Eastern Spadefoot Toad. The company is based in Wayland, MA. The company's mission is to conserve and care for forests, farms, and riverways of the Pioneer Valley while nurturing an enduring love of the land. The CEO of the company is Frank G. Haluska. | Director/Board Member | - |
Formation de Denis Patrick
| University of Pennsylvania | Doctorate Degree |
| SUNY Empire State College | Undergraduate Degree |
| University of California San Diego | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| PFIZER, INC. | Health Technology |
| Entreprise privées | 8 |
|---|---|
Pfizer Venture Investments LLC
Pfizer Venture Investments LLC Investment ManagersFinance Pfizer Ventures Investments LLC (Pfizer Ventures Investments) is a venture capital subsidiary of Pfizer Inc. founded in 2001. The firm is headquartered in New York. | Finance |
MISSION Therapeutics Ltd.
MISSION Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology MISSION Therapeutics Ltd. develops small molecule drugs targeting enzymes involved in cancer and other diseases. It focuses on selectively targeting deubiquitylating enzymes to treat cancer, neurodegenerative and other diseases. The company was founded by Stephen Jackson Philip, Xavier Jacq, Niall M. B. Martin and Keith Menear in 2011 and is headquartered in Cambridge, the United Kingdom. | Health Technology |
eFFECTOR Therapeutics Operations, Inc.
eFFECTOR Therapeutics Operations, Inc. Miscellaneous Commercial ServicesCommercial Services eFFECTOR Therapeutics Operations, Inc. discovers and develops translation regulators. It offers small molecule therapeutics that control gene expression for the treatment of cancer and other serious diseases. Its pipeline of translation regulators includes eFT508, eIF4E, and eIF4A. The company was founded by James R. Appleman, Kevin L. Eastwood, Siegfried Reich, Davide Ruggero, Kevan Shokat, and Stephen T. Worland in 2012 and is headquartered in San Diego, CA. | Commercial Services |
Metabomed Ltd.
Metabomed Ltd. Pharmaceuticals: MajorHealth Technology Metabomed Ltd. operates as a drug discovery company. It focuses in the field of cancer metabolism with a proprietary target identification platform based on computational biology and metabolomics. The company was founded by Eytan Ruppin, Tomer Shlomi and Eyal Gottlieb in 2013 and is headquartered in Yavne, Israel. | Health Technology |
Palleon Pharmaceuticals, Inc.
Palleon Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Palleon Pharmaceuticals, Inc. operates as biotechnology company. The firm discovers and develops immuno-oncology drugs, medicines, and therapies for the treatment of cancer diseases. It specializes in clinical development, and glyco-immune checkpoint inhibitors. The company was founded by Jim Broderick, Carolyn Bertozzi and Paul Crocker in 2015 and is headquartered in Waltham, MA. | Commercial Services |
Evolveimmune Therapeutics, Inc.
Evolveimmune Therapeutics, Inc. BiotechnologyHealth Technology EvolveImmune Therapeutics Inc. engages in the provision of healthcare services. It offers immunotherapy platform to develop molecules for the treatment of oncology and immune diseases. The company was founded in 2019 and is headquartered in Westport, CT. | Health Technology |
FoRx Therapeutics AG
FoRx Therapeutics AG Pharmaceuticals: MajorHealth Technology FoRx Therapeutics AG operates as a biotechnology company developing a new generation of cancer drugs focusing on novel deoxyribonucleic acid (DNA) Replication Stress pathways activated in cancer. The firm also provides research and development services. The company was founded by Thanos Halazonetis and Sotirios K. Sotiriou in 2019 and is headquartered in Basel, Switzerland. | Health Technology |
Kestrel Therapeutics, Inc.
Kestrel Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Kestrel Therapeutics, Inc. is a company that has two habitat restoration projects aimed at helping native animals that are at risk, specifically the American Kestrel and the Eastern Spadefoot Toad. The company is based in Wayland, MA. The company's mission is to conserve and care for forests, farms, and riverways of the Pioneer Valley while nurturing an enduring love of the land. The CEO of the company is Frank G. Haluska. | Commercial Services |
